Failing to deliver: the homecare services putting patients at risk - The Pharmaceutical Journal
The Pharmaceutical Journal from the Royal Pharmaceutical Society
Source: pharmaceutical-journal.com
📰 Access Pathway News
Page 3 - Access Pathway News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Access Pathway. Real-time updates on events, politics, business and more.
Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today
/PRNewswire/ -- BioArctic ABs (publ) (NASDAQ; BIOA B) (Stockholm: BIOA B) partner Eisai today held a presentation on the second quarter of Eisais fiscal...
Source: prnewswire.com
LEQEMBI® Q3 2023 sales published - 0.4 billion yen recorded in the period
/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing LEQEMBI sales for the third...
Source: prnewswire.com
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
-Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 202...
Source: businessinsider.com
COMPASS Pathways Q3 2023 Results: Cash Injection To Sustain Phase 3 Psilocybin Program - Compass Pathways (NASDAQ:CMPS)
COMPASS Pathways plc (NASDAQ: CMPS), the London-headquartered psychedelics biotech company reported financial results for the third quarter 2023 ended September 30, showing: 
Source: benzinga.com
Awakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder
Awakn Life Sciences Corp. , a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder , announces it has engaged Orphan...
Source: marketscreener.com
New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD
/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data on the investigational subcutaneous formulation of...
Source: prnewswire.com
New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD (1)
STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...
Source: europapress.es
New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD (2)
STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...
Source: europapress.es
EISAI - LEQEMBI NAMED ONE OF TIME'S BEST INVENTIONS OF 2023
NUTLEY - Eisai Inc. and Biogen Inc. are honored to announce today that TIME has selected LEQEMBI as one of the Best Inventions of 2023 in the Medical Care category. LEQEMBI is the first and only...
Source: marketscreener.com